Meeting
2017 Gastrointestinal Cancers Symposium
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
Authors
Vincent J. Picozzi
Virginia Mason Medical Center, Seattle, WA
Vincent J. Picozzi , Flavio G. Rocha , Scott Helton , Michael J. Pishvaian , Patrick G Jackson , Kabir Mody , Horacio Asbun , Mairead Carney , Tina Etheridge , Thomas B Neff , Seth Porter , Ming Zhong , Frank Valone , Elias Kouchakji , Joanne C. Imperial , Ewa Carrier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02210559
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 365)
DOI
10.1200/JCO.2017.35.4_suppl.365
Abstract #
365
Poster Bd #
G13
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
First Author: Vincent J. Picozzi
Poster
2015 Gastrointestinal Cancers Symposium
A randomized, open-label, phase I/II trial of gemcitabine plus nab-paclitaxel with or without FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer.
First Author: Flavio G. Rocha
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez